文献速递肾小球疾病

NELL1自身抗体的定量血清学检测在膜性肾病中的应用

Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy.
PubMed 文献 · Kidney Int · 2026-06-18

本研究开发了一种基于荧光素酶免疫沉淀系统(LIPS)的检测方法,用于定量检测循环NELL1自身抗体。在验证队列中,该检测对活检证实的NELL1阳性膜性肾病患者显示90%灵敏度和100%特异性,且纵向分析显示抗体水平与蛋白尿变化一致。

要点

  • LIPS法检测NELL1抗体在验证队列中灵敏度90%、特异性100%。
  • N端片段(氨基酸1-550)诊断性能优于全长NELL1。
  • 抗体水平纵向变化与蛋白尿相关,可用于监测治疗反应。

核心结论

  • NELL1 LIPS检测为NELL1相关膜性肾病提供无创诊断工具,并可监测治疗反应。

研究设计与样本

  • 开发LIPS免疫检测法,使用活检证实的NELL1阳性验证队列血清评估诊断性能,并在独立NIH队列中检测NELL1血清阳性及纵向样本抗体动态。

主要发现

  • 验证队列(20例活检证实的NELL1阳性与20例PLA2R阳性/NELL1阴性患者)中,LIPS法灵敏度90%、特异性100%。
  • NIH队列中63例MN和20例疾病对照检出6例NELL1阳性MN。
  • 3例NELL1血清阳性患者的纵向分析显示自身抗体水平与蛋白尿变化一致。

关键数值与推荐

  • 验证队列:灵敏度90%,特异性100%,与ELISA结果一致但特异性更优。
  • 最佳抗原区域为NELL1 N端片段(氨基酸1-550)融合Gaussia荧光素酶。

临床怎么用

  • 可用于无创诊断NELL1相关膜性肾病,并像PLA2R抗体一样通过监测抗体滴度辅助临床管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Membranous nephropathy (MN) comprises distinct subtypes driven by autoantibodies targeting podocyte-associated proteins, one of which is neural EGFL-like 1 (NELL1). Currently, the diagnosis of NELL1-associated MN relies mainly on mass spectrometry or immunostaining of kidney biopsies. Serologic testing for anti-NELL1 antibodies is not yet commercially available, but research assays including Western blotting, indirect immunofluorescence, and ELISA have recently been developed. However, these are currently performed only in research settings, and ELISA may not be sufficiently specific for primary diagnostic purposes. High-throughput immunoassays are needed for the diagnosis and monitoring of NELL1 autoantibody-positive patients with MN. METHODS: Here, we developed a luciferase immunoprecipitation systems (LIPS) immunoassay to detect circulating NELL1 autoantibodies. After identifying the optimal antigenic region of NELL1, we evaluated the assay's diagnostic performance using serum samples derived from a biopsy-proven NELL1+ validation cohort. We then assessed NELL1 seropositivity in an independent NIH clinical evaluation cohort and examined antibody dynamics in longitudinal samples from selected positive cases. RESULTS: Initial assay development using known NELL1 positive sera demonstrated an N-terminal fragment of NELL1 protein (amino acids 1-550) fused to Gaussia luciferase yielded superior diagnostic performance compared with full-length NELL1 (810 amino acids). In a validation cohort consisting of sera from 20 biopsy-proven NELL1-positive and 20 PLA2R+/NELL1-negative patients, this LIPS assay showed 90% sensitivity and 100% specificity and showed agreement with ELISA but with better specificity. Further testing of 63 MN cases and 20 disease controls from the NIH cohort identified six NELL1-positive MN cases. Longitudinal analysis of three NELL1 seropositive cases revealed that autoantibody levels tracked proteinuria, suggesting that monitoring antibody titers may be useful in clinical management like that with PLA2R antibodies. CONCLUSIONS: Our NELL1 LIPS assay provides a noninvasive tool for diagnosing NELL1-associated MN, characterizing clinical subsets, and monitoring therapeutic response.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Burbelo PD, Howard L, Caza TN, et al. Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy. Kidney Int. 2026. PMID: 42315018. doi:10.1016/j.kint.2026.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。